News

CXCL4 and CXCL7 expression increases in early stages of RA


 

References

Expression of the CXCL4 and CXCL7 chemokines seems to be increased in the early stages of rheumatoid arthritis, according to Dr. Lorraine Yeo of the University of Birmingham, England, and her associates.

Compared to patients in the non-inflamed control group, those with early RA had significantly higher mRNA levels of the CXCL4 and CXCL7 chemokines. Protein expression of the two chemokines was also much higher in patients with early RA compared to those whose arthritis was resolving or had long established RA. Significantly elevated extravascular CXCL7 levels were also present in early RA patients.

“It will be important to investigate whether the production of CXCL4 and CXCL7 observed in the synovium in early RA is reflected by elevated levels in plasma samples. Future use of these chemokines as biomarkers for prediction of progression to RA will depend on replication in other independent cohorts,” the investigators concluded.Find the full study in Annals of the Rheumatic Diseases (doi:10.1136/annrheumdis-2014-206921).

Recommended Reading

Infliximab most common cause of drug-induced liver injury
MDedge Rheumatology
What’s new with methotrexate for rheumatoid arthritis
MDedge Rheumatology
VIDEO: True remission necessary before tapering or discontinuing RA drugs
MDedge Rheumatology
Microbiome research is decades away from benefiting human health
MDedge Rheumatology
Diet’s link to RA risk centers on alcohol, fish, sugar consumption
MDedge Rheumatology
Anti-interleukin 20 antibody effective for active RA
MDedge Rheumatology
MicroRNAs may prove helpful as a rheumatoid arthritis therapy biomarker
MDedge Rheumatology
Treat-to-target approach for RA has cardiovascular benefits
MDedge Rheumatology
Home-administered biologics for RA more common with Medicare Part D subsidies
MDedge Rheumatology
Rheumatologists support biosimilars, with caveats
MDedge Rheumatology